Synthetic Biologics, a developer of therapeutics to protect the microbiome while targeting pathogen-specific diseases, has a new Senior Vice President, Manufacturing.
Raymond Stapleton will lead the manufacturing team as the company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programmes, and continues to move its monoclonal antibody (mAb) programme forward to address Pertussis (whooping cough).
Dr Stapleton is a pharmaceutical and biotechnology executive with more than 15 years of experience at Merck & Co in manufacturing, operations, quality, science, technology, engineering and process development. Most recently he was Executive Director, Global Vaccine Technology and Engineering.
